192 related articles for article (PubMed ID: 27698247)
21. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
22. Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods.
Ara R; Brazier J
Med Care; 2012 May; 50(5):452-9. PubMed ID: 22002647
[TBL] [Abstract][Full Text] [Related]
23. Direct and indirect economic consequences of multiple sclerosis in Ireland.
Fogarty E; Walsh C; McGuigan C; Tubridy N; Barry M
Appl Health Econ Health Policy; 2014 Dec; 12(6):635-45. PubMed ID: 25227118
[TBL] [Abstract][Full Text] [Related]
24. Health-related quality of life and utilities among Lebanese patients with Multiple Sclerosis: A cross-sectional study.
Dahham J; Hiligsmann M; Kremer I; Khoury SJ; Darwish H; Hosseini H; Hallit S; Evers S; Rizk R
Mult Scler Relat Disord; 2024 Jun; 86():105635. PubMed ID: 38640585
[TBL] [Abstract][Full Text] [Related]
25. Costs and quality of life of multiple sclerosis in Sweden.
Berg J; Lindgren P; Fredrikson S; Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S75-85. PubMed ID: 17310342
[TBL] [Abstract][Full Text] [Related]
26. Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
[TBL] [Abstract][Full Text] [Related]
27. Health utilities and quality of life in individuals with tuberous sclerosis complex (TSC) who experience epileptic seizures: A web-based survey.
Tritton T; Bennett B; Brohan E; Grant L; Cooper A; Fladrowski C; Evanochko C; Neary M; Vieira J; Buffa V; Kingswood C
Epilepsy Behav; 2019 Mar; 92():213-220. PubMed ID: 30690322
[TBL] [Abstract][Full Text] [Related]
28. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
29. EQ-5D-Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review.
Golicki D; Jaśkowiak K; Wójcik A; Młyńczak K; Dobrowolska I; Gawrońska A; Basak G; Snarski E; Hołownia-Voloskova M; Jakubczyk M; Niewada M
Value Health; 2020 Jul; 23(7):953-968. PubMed ID: 32762998
[TBL] [Abstract][Full Text] [Related]
30. Burden and health state utility values of eating disorders: results from a population-based survey.
Le LK; Mihalopoulos C; Engel L; Touyz S; González-Chica DA; Stocks N; Hay P
Psychol Med; 2021 Jan; 51(1):130-137. PubMed ID: 31670627
[TBL] [Abstract][Full Text] [Related]
31. Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability.
Casado V; Martínez-Yélamos S; Martínez-Yélamos A; Carmona O; Alonso L; Romero L; Moral E; Gubieras L; Arbizu T
BMC Health Serv Res; 2006 Nov; 6():143. PubMed ID: 17078879
[TBL] [Abstract][Full Text] [Related]
32. Change in disability profile and quality of life in multiple sclerosis patients: a five-year longitudinal study using the Multiple Sclerosis Impact Profile (MSIP).
Wynia K; van Wijlen AT; Middel B; Reijneveld SA; Meilof JF
Mult Scler; 2012 May; 18(5):654-61. PubMed ID: 21965423
[TBL] [Abstract][Full Text] [Related]
33. Health State Utility Values in Schizophrenia: A Systematic Review and Meta-Analysis.
Aceituno D; Pennington M; Iruretagoyena B; Prina AM; McCrone P
Value Health; 2020 Sep; 23(9):1256-1267. PubMed ID: 32940244
[TBL] [Abstract][Full Text] [Related]
34. Mapping the COPD Assessment Test onto EQ-5D.
Hoyle CK; Tabberer M; Brooks J
Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
[TBL] [Abstract][Full Text] [Related]
35. Health state utility values among children and adolescents with disabilities: protocol for a systematic review.
Kanya L; Anokye N; Ryan JM
BMJ Open; 2018 Feb; 8(2):e019978. PubMed ID: 29467137
[TBL] [Abstract][Full Text] [Related]
36. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample.
Idiman E; Uzunel F; Ozakbas S; Yozbatiran N; Oguz M; Callioglu B; Gokce N; Bahar Z
J Neurol Sci; 2006 Jan; 240(1-2):77-80. PubMed ID: 16277993
[TBL] [Abstract][Full Text] [Related]
37. The cost of multiple sclerosis in Australia.
Taylor B; McDonald E; Fantino B; Sedal L; MacDonnell R; Pittas F; Groom T; Beresniak A
J Clin Neurosci; 2007 Jun; 14(6):532-9. PubMed ID: 17430777
[TBL] [Abstract][Full Text] [Related]
38. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review.
Brockbank J; Krause T; Moss E; Pedersen AM; Mørup MF; Ahdesmäki O; Vaughan J; Brodtkorb TH
Health Qual Life Outcomes; 2021 Mar; 19(1):94. PubMed ID: 33736649
[TBL] [Abstract][Full Text] [Related]
39. Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.
Palmer AJ; van der Mei I; Taylor BV; Clarke PM; Simpson S; Ahmad H
Mult Scler; 2020 Apr; 26(4):411-420. PubMed ID: 30806569
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
